KOCAA
PVLA

Knights of Columbus Asset Advisors’s Palvella Therapeutics PVLA Stock Holding History

Knights of Columbus Asset Advisors’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.53M Buy
10,031
+2,273
+29% +$276K 0.08% 246
2026
Q1 		$967K Buy
+7,758
New +$809K 0.05% 270

Other funds holding PVLA

Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.85B AUM 140.52% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
CAM
Clio Asset Management Charlottesville, Virginia $126M AUM 16.01% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
LCM
Legato Capital Management San Francisco, California $1.21B AUM 82.36% 1-Year Est. Return

Knights of Columbus Asset Advisors's PVLA Position: Q2 2026 in Review

Knights of Columbus Asset Advisors increased its Palvella Therapeutics (PVLA) stake by 29% in Q2 2026, buying an estimated $276K and bringing the position to 10,031 shares worth $1.53M. The position accounts for 0.08% of the portfolio, ranked #246.

Knights of Columbus Asset Advisors first reported a position in PVLA in Q1 2026 and has held it in 2 quarters since. 63 funds tracked by Wall St. Rank hold PVLA as of Q2 2026.

  • Knights of Columbus Asset Advisors held 10,031 shares of Palvella Therapeutics worth $1.53M as of Q2 2026.
  • Knights of Columbus Asset Advisors bought 2,273 Palvella Therapeutics shares in Q2 2026, an estimated $276K.
  • Palvella Therapeutics made up 0.08% of Knights of Columbus Asset Advisors's portfolio in Q2 2026, its #246 holding.
  • Knights of Columbus Asset Advisors first reported a position in Palvella Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 63 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2026.

Based on Knights of Columbus Asset Advisors's 13F filing for Q2 2026, filed 31 Jul 2026.